ADORA2A and cancer: In our study, high ADORA2A expression was independently correlated with high PD-1 transcript expression, suggesting that mitigating the checkpoint effect in some cancers might require a combination of adenosine pathway inhibitors together with anti-PD-1 antibodies (Figure 1, panel B).